血糖异常与儿童及青少年造血干细胞移植患者不良结局相关
该回顾性队列纳入2007至2016年在科罗拉多儿童医院接受首次造血干细胞移植的344例0至30岁患者,分析血糖异常的发生率及与结局的关系。血糖异常发生率为43.9%,移植后第0至100天平均血糖100至124 mg/dL和≥125 mg/dL的患者死亡风险分别增加1.76倍和7.06倍,移植前血糖每升高10 mg/dL,移植后感染风险增加1.11倍。
要点
- 儿童及青少年造血干细胞移植患者血糖异常发生率为43.9%。
- 移植后第0至100天平均血糖100至124 mg/dL者死亡风险增加1.76倍,≥125 mg/dL者增加7.06倍。
- 移植前血糖每升高10 mg/dL,移植后感染风险增加1.11倍。
核心结论
- 儿童及青少年造血干细胞移植人群中,血糖异常与发病率和死亡率显著增加独立相关;需进一步研究评估血糖控制的效用,以减轻这些关联并改善移植结局。
研究设计与样本
- 回顾性队列研究,纳入2007至2016年在科罗拉多儿童医院接受首次造血干细胞移植的344例0至30岁患者,分析血糖数据并评估潜在危险因素和相关结局。
主要发现
- 血糖异常发生于43.9%的患者。
- 与第0至100天平均血糖<100 mg/dL的患者相比,平均血糖100至124 mg/dL的患者死亡风险增加1.76倍(95%CI 1.10-2.82;P=.02),平均血糖≥125 mg/dL的患者死亡风险增加7.06倍(95%CI 3.84-12.99;P<.0001)。
- 移植前血糖每升高10 mg/dL,移植后感染风险增加1.11倍(95%CI 1.04-1.18;P=.0013)。
- 血糖异常的不良影响独立于移植类型、移植物抗宿主病和类固醇治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Malglycemia (hypoglycemia, hyperglycemia, and/or glycemic variability) in adult hematopoietic stem cell transplant (HSCT) recipients is associated with increased infection, graft-versus-host disease, organ dysfunction, delayed engraftment, and mortality. Malglycemia has not been studied in pediatric HSCT recipients. This study aimed to characterize the incidence and consequences of malglycemia in this population. Medical records for a cohort of 344 patients, age 0 to 30 years, who underwent first HSCT from 2007 to 2016 at Children's Hospital Colorado were retrospectively reviewed. Glucose data were analyzed in intervals and assessed for potential risk factors and associated outcomes. Malglycemia occurred in 43.9% of patients. Patients with a day 0 to 100 mean glucose of 100 to 124 mg/dL had a 1.76-fold (95% confidence interval [CI], 1.10-2.82; P = .02) increased risk of death and patients with a day 0 to 100 mean glucose ≥ 125 mg/dL had a 7.06-fold (95% CI, 3.84-12.99; P < .0001) increased risk of death compared with patients with a day 0 to 100 mean glucose < 100 mg/dL. For each 10 mg/dL increase in pre-HSCT glucose, there was a 1.11-fold (95% CI, 1.04-1.18; P = .0013) increased risk of post-HSCT infection. These adverse impacts of malglycemia occurred independent of transplant type, graft-versus-host disease, and steroid therapy. Malglycemia in the pediatric HSCT population is independently associated with significantly increased risk of morbidity and mortality. Further research is required to evaluate the utility of glucose control to mitigate these relationships and improve HSCT outcomes. This trial was registered at www.clinicaltrials.gov as #NCT03482154.
引用
- Sopfe J, Pyle L, Keating AK, et al. Malglycemia is associated with poor outcomes in pediatric and adolescent hematopoietic stem cell transplant patients. Blood Adv. 2019. PMID: 30718242. doi:10.1182/bloodadvances.2018021014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。